Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy. Issue 6 (December 2015)

• Record Type: Journal Article
• Authors: Nakamura, Mashio; Yamada, Norikazu; Ito, Masaaki
• Is Part Of: Journal of cardiology. Volume 66:Issue 6(2015:Dec.)
• Page Start: 451
• Page End: 459
• Publication Date: 2015-12
• Subjects: Anticoagulation -- Deep vein thrombosis -- Nonvitamin K antagonist oral anticoagulant -- Venous thromboembolism -- Pulmonary embolism; Cardiology -- Periodicals; 616.12
• DOI: 10.1016/j.jjcc.2015.03.012
• Languages: English
• ISSNs: 0914-5087

Abstract

Abstract: Venous thromboembolism (VTE), manifesting as either deep vein thrombosis or pulmonary embolism, is common worldwide including in Japan. The number of patients clinically diagnosed with VTE is increasing with the majority of cases occurring out-of-hospital and of milder severity. Cancer is the largest risk factor for VTE and VTE in cancer patients confers an increased 1-year mortality rate. However, the majority of VTE cases are considered "idiopathic" or "unprovoked." The limited efficacies of unfractionated heparin and warfarin have stimulated the development of new anticoagulant therapies. Recently, parenteral and oral administration of the Xa inhibitors fondaparinux and edoxaban, respectively, was approved in Japan. These agents have the potential to provide safer and more efficacious treatment options for VTE. Although further randomized studies are required to validate the utility of these agents, they are expected to substantially improve quality of life in VTE patients. This review summarizes the current status of VTE management in Japan focusing on current epidemiology and recent advances in anticoagulant therapy.